vs
Side-by-side financial comparison of Jazz Pharmaceuticals plc (JAZZ) and M/I HOMES, INC. (MHO). Click either name above to swap in a different company.
Jazz Pharmaceuticals plc is the larger business by last-quarter revenue ($1.2B vs $1.1B, roughly 1.0× M/I HOMES, INC.). Jazz Pharmaceuticals plc runs the higher net margin — 17.0% vs 5.6%, a 11.4% gap on every dollar of revenue. On growth, Jazz Pharmaceuticals plc posted the faster year-over-year revenue change (10.1% vs -4.8%). Jazz Pharmaceuticals plc produced more free cash flow last quarter ($345.8M vs $-13.0M). Over the past eight quarters, Jazz Pharmaceuticals plc's revenue compounded faster (15.2% CAGR vs 4.7%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
M/I Homes, Inc. is a leading U.S. residential construction company that designs, builds and sells single-family homes, townhomes and duplexes across multiple U.S. states. It caters to entry-level, move-up and luxury homebuyers, offering energy-efficient designs, flexible floor plans and personalized customization options.
JAZZ vs MHO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $1.1B |
| Net Profit | $203.5M | $64.0M |
| Gross Margin | — | 17.4% |
| Operating Margin | 21.2% | 6.5% |
| Net Margin | 17.0% | 5.6% |
| Revenue YoY | 10.1% | -4.8% |
| Net Profit YoY | 6.5% | -52.1% |
| EPS (diluted) | $3.34 | $2.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2B | $1.1B | ||
| Q3 25 | $1.1B | $1.1B | ||
| Q2 25 | $1.0B | $1.2B | ||
| Q1 25 | $897.8M | $976.1M | ||
| Q4 24 | $1.1B | $1.2B | ||
| Q3 24 | $1.1B | $1.1B | ||
| Q2 24 | $1.0B | $1.1B | ||
| Q1 24 | $902.0M | $1.0B |
| Q4 25 | $203.5M | $64.0M | ||
| Q3 25 | $251.4M | $106.5M | ||
| Q2 25 | $-718.5M | $121.2M | ||
| Q1 25 | $-92.5M | $111.2M | ||
| Q4 24 | $191.1M | $133.5M | ||
| Q3 24 | $215.1M | $145.4M | ||
| Q2 24 | $168.6M | $146.7M | ||
| Q1 24 | $-14.6M | $138.1M |
| Q4 25 | — | 17.4% | ||
| Q3 25 | — | 24.5% | ||
| Q2 25 | — | 24.7% | ||
| Q1 25 | — | 25.9% | ||
| Q4 24 | — | 24.6% | ||
| Q3 24 | — | 27.1% | ||
| Q2 24 | — | 27.9% | ||
| Q1 24 | — | 27.1% |
| Q4 25 | 21.2% | 6.5% | ||
| Q3 25 | 5.1% | 12.0% | ||
| Q2 25 | -65.6% | 13.4% | ||
| Q1 25 | -6.2% | 14.4% | ||
| Q4 24 | 17.5% | 13.6% | ||
| Q3 24 | 24.7% | 15.9% | ||
| Q2 24 | 19.5% | 16.8% | ||
| Q1 24 | 7.3% | 16.6% |
| Q4 25 | 17.0% | 5.6% | ||
| Q3 25 | 22.3% | 9.4% | ||
| Q2 25 | -68.7% | 10.4% | ||
| Q1 25 | -10.3% | 11.4% | ||
| Q4 24 | 17.6% | 11.1% | ||
| Q3 24 | 20.4% | 12.7% | ||
| Q2 24 | 16.5% | 13.2% | ||
| Q1 24 | -1.6% | 13.2% |
| Q4 25 | $3.34 | $2.42 | ||
| Q3 25 | $4.08 | $3.92 | ||
| Q2 25 | $-11.74 | $4.42 | ||
| Q1 25 | $-1.52 | $3.98 | ||
| Q4 24 | $2.97 | $4.71 | ||
| Q3 24 | $3.42 | $5.10 | ||
| Q2 24 | $2.49 | $5.12 | ||
| Q1 24 | $-0.23 | $4.78 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.4B | — |
| Total DebtLower is stronger | $5.4B | — |
| Stockholders' EquityBook value | $4.3B | $3.2B |
| Total Assets | $11.7B | $4.8B |
| Debt / EquityLower = less leverage | 1.24× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.9B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $1.4B | — | ||
| Q1 24 | $1.4B | — |
| Q4 25 | $5.4B | — | ||
| Q3 25 | $5.4B | — | ||
| Q2 25 | $5.4B | — | ||
| Q1 25 | $5.4B | — | ||
| Q4 24 | $6.1B | — | ||
| Q3 24 | $6.1B | — | ||
| Q2 24 | $5.7B | — | ||
| Q1 24 | $5.7B | — |
| Q4 25 | $4.3B | $3.2B | ||
| Q3 25 | $4.0B | $3.1B | ||
| Q2 25 | $3.7B | $3.1B | ||
| Q1 25 | $4.2B | $3.0B | ||
| Q4 24 | $4.1B | $2.9B | ||
| Q3 24 | $4.2B | $2.8B | ||
| Q2 24 | $3.8B | $2.7B | ||
| Q1 24 | $3.7B | $2.6B |
| Q4 25 | $11.7B | $4.8B | ||
| Q3 25 | $11.4B | $4.8B | ||
| Q2 25 | $10.9B | $4.7B | ||
| Q1 25 | $11.5B | $4.6B | ||
| Q4 24 | $12.0B | $4.5B | ||
| Q3 24 | $12.3B | $4.5B | ||
| Q2 24 | $11.4B | $4.3B | ||
| Q1 24 | $11.3B | $4.2B |
| Q4 25 | 1.24× | — | ||
| Q3 25 | 1.35× | — | ||
| Q2 25 | 1.45× | — | ||
| Q1 25 | 1.29× | — | ||
| Q4 24 | 1.49× | — | ||
| Q3 24 | 1.47× | — | ||
| Q2 24 | 1.52× | — | ||
| Q1 24 | 1.54× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $362.5M | $-8.7M |
| Free Cash FlowOCF − Capex | $345.8M | $-13.0M |
| FCF MarginFCF / Revenue | 28.9% | -1.1% |
| Capex IntensityCapex / Revenue | 1.4% | 0.4% |
| Cash ConversionOCF / Net Profit | 1.78× | -0.14× |
| TTM Free Cash FlowTrailing 4 quarters | $1.3B | $127.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $362.5M | $-8.7M | ||
| Q3 25 | $474.6M | $43.4M | ||
| Q2 25 | $88.9M | $37.8M | ||
| Q1 25 | $429.8M | $64.9M | ||
| Q4 24 | $398.6M | $104.4M | ||
| Q3 24 | $398.7M | $-67.9M | ||
| Q2 24 | $331.4M | $27.5M | ||
| Q1 24 | $267.2M | $115.8M |
| Q4 25 | $345.8M | $-13.0M | ||
| Q3 25 | $459.4M | $42.0M | ||
| Q2 25 | $75.9M | $35.1M | ||
| Q1 25 | $415.9M | $63.5M | ||
| Q4 24 | $385.3M | $102.3M | ||
| Q3 24 | $388.0M | $-68.5M | ||
| Q2 24 | $324.3M | $22.0M | ||
| Q1 24 | $260.3M | $115.5M |
| Q4 25 | 28.9% | -1.1% | ||
| Q3 25 | 40.8% | 3.7% | ||
| Q2 25 | 7.3% | 3.0% | ||
| Q1 25 | 46.3% | 6.5% | ||
| Q4 24 | 35.4% | 8.5% | ||
| Q3 24 | 36.8% | -6.0% | ||
| Q2 24 | 31.7% | 2.0% | ||
| Q1 24 | 28.9% | 11.0% |
| Q4 25 | 1.4% | 0.4% | ||
| Q3 25 | 1.3% | 0.1% | ||
| Q2 25 | 1.2% | 0.2% | ||
| Q1 25 | 1.5% | 0.1% | ||
| Q4 24 | 1.2% | 0.2% | ||
| Q3 24 | 1.0% | 0.1% | ||
| Q2 24 | 0.7% | 0.5% | ||
| Q1 24 | 0.8% | 0.0% |
| Q4 25 | 1.78× | -0.14× | ||
| Q3 25 | 1.89× | 0.41× | ||
| Q2 25 | — | 0.31× | ||
| Q1 25 | — | 0.58× | ||
| Q4 24 | 2.09× | 0.78× | ||
| Q3 24 | 1.85× | -0.47× | ||
| Q2 24 | 1.97× | 0.19× | ||
| Q1 24 | — | 0.84× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
MHO
| Southern Homebuilding | $615.6M | 54% |
| Northern Homebuilding | $503.9M | 44% |
| Financial Service | $27.8M | 2% |
| Land | $4.7M | 0% |
